Background And Objective: Today, the role of oxidative stress in development of schizophrenia has gained attention. Also, some atypical antipsychotic agents showed antioxidant properties. Therefore, in this study, we evaluated the level of oxidative stress parameters between patients treated with perphenazine, clozapine and risperidone and their relationship with schizophrenia symptoms' severity.
Materials And Methods: This was a descriptive study on 100 patients with chronic schizophrenia. Patient selection was done based on the DSM-IV-TR criteria for at least 3 months regular use of clozapine or risperidone or perphenazine and a minimum period of 2 years of schizophrenia. Ten ml of patient's blood samples were used to assess serum levels of glutathione (GSH), protein carbonyl, lipid peroxidation (LPO), superoxide dismutase (SOD) and Ferric Reducing Ability of Plasma (FRAP). Also, the severity of symptoms was assessed with the positive and negative syndrome scale (PANSS scale). P-values of less than 0.05 were considered significant.
Results: The results showed a significant difference between clozapine and risperidone with perphenazine in all subscales of PANSS. Also, there was a positive correlation between MDA and PANSS all subscales in risperidone and perphenazine groups and a negative correlation between MDA and PANSS in all subscales in the clozapine group. Serum level of GSH and negative symptoms in patients receiving clozapine showed a negative correlation. The results also represented that clozapine significantly increased SOD levels in comparison to perphenazine and risperidone and reduced LPO in comparison to perphenazine and risperidone, While the protein carbonyl level did not show a significant difference between three groups (p-value = 0.8).
Conclusion: This study showed that clozapine, as an atypical antipsychotic agent, has significant antioxidant effects compared to risperidone and perphenazine. Especially, it increased SOD and GSH levels and reduced LPO in patients with schizophrenia. Therefore, clozapine's antioxidant effect may be contributive to improving negative symptoms of schizophrenic patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biopha.2018.04.109 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antipsychotic use during pregnancy and outcomes in pregnant individuals and newborns.
J Affect Disord
January 2025
Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea; Department of Regulatory Science, Kyung Hee University, Seoul, South Korea; Department of Pediatrics, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea. Electronic address:
Background: Despite the increasing use of antipsychotics during pregnancy, comprehensive evaluations of their individual safety profiles using global data remain limited. This study aimed to assess the safety of various antipsychotics during pregnancy by comparing them to quetiapine, which has a relatively large body of safety data.
Method: Utilizing the World Health Organization pharmacovigilance database (1967-2023; n = 131,255,418 reports), we identified 11,406 reports of antipsychotic exposure during pregnancy.
Background: This scoping review focuses on the occurrence of tachyphylaxis, defined as reduced responsiveness upon reinitiating a previously effective medication. This phenomenon is previously documented in antidepressants and mood stabilizers.
Aim: To explore the frequency, treatment strategies, and predictability of tachyphylaxis across all psychotropic medications.
Adiponectin, resistin, interleukin-4 and TGF-β2 levels in treatment resistant schizophrenia patients.
Prog Neuropsychopharmacol Biol Psychiatry
December 2024
Department of Psychiatry, Faculty of Medicine, School of Health Sciences, University of Ioannina (UOI), P.O. Box 1186, 45110 Ioannina, Greece. Electronic address:
Background: The aim of the present study was to measure adiponectin, resistin, interleukin-4 and TGF-β levels in first episode, treatment resistant patients with schizophrenia.
Methods: In total, fifty-three treatment-resistant patients were included in the study. In subgroups of these patients, we measured Interleukin-4 (IL-4), Tumor Growth Factor-β2 (TGF-β2), adiponectin and resistin levels at three different timepoints: in the drug-naïve state, after two rounds of treatment with different antipsychotic drugs for a total of 16 weeks and, after clozapine treatment for 12 weeks.
Real-World Treatment of Schizophrenia in Adults With a 22q11.2 Microdeletion: Traitement dans le monde réel de la schizophrénie chez des adultes atteints du syndrome de microdélétion 22q11.2.
Can J Psychiatry
December 2024
The Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Objective: One in every 4 individuals born with a 22q11.2 microdeletion will develop schizophrenia. Thirty years of clinical genetic testing capability have enabled detection of this major molecular susceptibility for psychotic illness.
View Article and Find Full Text PDFAlterations in regional homogeneity in schizophrenia patients comorbid with metabolic syndrome treated with risperidone or clozapine.
J Psychiatr Res
November 2024
Department of Radiology, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, China. Electronic address:
The neuroimaging mechanisms that arise in patients with schizophrenia and comorbid metabolic syndrome (MetS) remain poorly understood. This study was devised to examine potential alterations in regional homogeneity (ReHo) that arise in schizophrenia patients with comorbid MetS undergoing risperidone or clozapine treatment. In total, 43 schizophrenia patients undergoing risperidone or clozapine treatment were enrolled in this study, of whom 20 had comorbid MetS (SZ-MetS) while 23 did not (SZ-nMetS).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!